Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 10642349)

1.

Arterial stiffness and cardiovascular therapy.

Janić M, Lunder M, Sabovič M.

Biomed Res Int. 2014;2014:621437. doi: 10.1155/2014/621437. Epub 2014 Aug 7. Review.

2.

The vascular depression hypothesis: mechanisms linking vascular disease with depression.

Taylor WD, Aizenstein HJ, Alexopoulos GS.

Mol Psychiatry. 2013 Sep;18(9):963-74. doi: 10.1038/mp.2013.20. Epub 2013 Feb 26. Review.

3.

The eye and the heart.

Flammer J, Konieczka K, Bruno RM, Virdis A, Flammer AJ, Taddei S.

Eur Heart J. 2013 May;34(17):1270-8. doi: 10.1093/eurheartj/eht023. Epub 2013 Feb 10. Review.

4.

Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial.

Hajjar I, Hart M, Chen YL, Mack W, Novak V, C Chui H, Lipsitz L.

J Am Geriatr Soc. 2013 Feb;61(2):194-201. doi: 10.1111/jgs.12100. Epub 2013 Jan 25.

5.

Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial.

Hajjar I, Hart M, Chen YL, Mack W, Milberg W, Chui H, Lipsitz L.

Arch Intern Med. 2012 Mar 12;172(5):442-4. doi: 10.1001/archinternmed.2011.1391. No abstract available.

6.

Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.

Mason RP, Jacob RF, Kubant R, Jacoby A, Louka F, Corbalan JJ, Malinski T.

Br J Clin Pharmacol. 2012 Jul;74(1):141-6. doi: 10.1111/j.1365-2125.2012.04189.x.

7.

Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway.

Shatanawi A, Romero MJ, Iddings JA, Chandra S, Umapathy NS, Verin AD, Caldwell RB, Caldwell RW.

Am J Physiol Cell Physiol. 2011 May;300(5):C1181-92. doi: 10.1152/ajpcell.00328.2010. Epub 2011 Feb 2.

8.

Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature.

Schiffrin EL.

J Cell Mol Med. 2010 May;14(5):1018-29. doi: 10.1111/j.1582-4934.2010.01056.x. Epub 2010 Mar 19. Review.

9.

Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes.

Larrayoz IM, Pang T, Benicky J, Pavel J, Sánchez-Lemus E, Saavedra JM.

J Hypertens. 2009 Dec;27(12):2365-76. doi: 10.1097/HJH.0b013e3283314bc7.

10.

Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.

Tzemos N, Lim PO, MacDonald TM.

Cardiovasc Ther. 2009 Fall;27(3):151-8. doi: 10.1111/j.1755-5922.2009.00085.x. Epub 2009 Jul 14.

11.
12.

Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo.

Dasu MR, Riosvelasco AC, Jialal I.

Atherosclerosis. 2009 Jan;202(1):76-83. doi: 10.1016/j.atherosclerosis.2008.04.010. Epub 2008 Apr 18.

13.

Ageing reduces nitric-oxide- and prostaglandin-mediated vasodilatation in exercising humans.

Schrage WG, Eisenach JH, Joyner MJ.

J Physiol. 2007 Feb 15;579(Pt 1):227-36. Epub 2006 Nov 30.

14.

Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients.

Park CG, Ahn JC, Hong SJ, Kim EJ, Lee SJ, Park SM, Seo HS, Oh DJ.

Korean J Intern Med. 2006 Jun;21(2):103-8. Erratum in: Korean J Intern Med. 2010 Mar;25(1):118. Park, Sung Mi [corrected to Park, Seong Mi].

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk